Incorrect Residual Heparin Amount: In the Original Contribution entitled “Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction: The TIME Randomized Trial,” published in the December 12, 2012, issue of JAMA (2012;308[22]:2380-2389), under the Results heading, third full paragraph, the third sentence should have stated, “The cell product was devoid of significant red blood cell contamination, contained only minuscule amounts of heparin (estimated at 0.01 U/mL), and most participants were infused within 1 hour of completion of cell processing,11 thereby avoiding concerns recently expressed in the literature.12,13” This article has been corrected online.